Overview
- GRAIL disclosed on Feb. 19, 2026 that the NHS‑Galleri study did not meet its primary endpoint and acknowledged the three‑year follow‑up probably was too short to show a late‑stage cancer reduction.
- The market reacted the next day with GRAIL shares falling more than 50% and an estimated $2.2 billion or more in market capitalization lost.
- Several plaintiff firms have filed or opened investigations and are soliciting shareholders who bought stock from May 13, 2025 through Feb. 19, 2026, with an August 4, 2026 deadline to seek lead‑plaintiff status.
- Complaints allege GRAIL gave investors an overly positive picture of the trial’s design and repeatedly declined to provide detailed topline results or other data that could have signaled the need for a longer follow‑up.
- No class has been certified and outcomes remain uncertain, but the litigation could affect investor recoveries, prompt closer scrutiny of how clinical trial toplines are reported, and encourage whistleblower tips to regulators.